Here, treatment with abatacept significantly enhanced the level of IL-35+IL-10+ Bregs (EBi3+IL-10+ cells within CD19+CD138+CD1d+) in peripheral blood of treated compared to RA patients not on abatacept (Fig. 2C; P = 0.0007). The gene discussed is CD19; the disease is rheumatoid arthritis.